Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 50
Filter
1.
Med Oncol ; 32(3): 52, 2015 Mar.
Article in English | MEDLINE | ID: mdl-25636506

ABSTRACT

The aim of this paper was to evaluate the activity and tolerability of weekly docetaxel (D) combined with weekly epirubicin (EPI) in patients with advanced castrate-resistant prostate cancer (CRPC) previously exposed to D and abiraterone acetate (AA). Locally advanced or metastatic CRPC patients with 0-2 performance status, who had progressed after D and AA therapy, were included in the study. Previous treatment with chemotherapy agent cabazitaxel was also admitted. Treatment consisted of D 30 mg/m(2) intravenously (i.v.) and EPI 30 mg/m(2) i.v., every week (D/EPI). Chemotherapy was administered until disease progression or unacceptable toxicity. In our institution, twenty-six patients received D/EPI: their median age was 72 years (range 59-83 years). Twenty-three (88.5%) patients had bone metastases. A decrease in PSA levels ≥50% was observed in seven patients (26.9%, 95% CI: 0.11-0.47); of these, five had achieved a ≥50% PSA response during prior first-line D and six had achieved a PSA response during prior AA Among the subjects who were symptomatic at baseline, pain was reduced in nine patients (38.1%) with a significant decrease in analgesic use. Median progression-free survival was 4.4 months (95% CI, 3-5.2), and median overall survival was 10.7 months (95% CI, 8.9-18.4). Treatment was well tolerated and no grade 4 toxicities were observed. Our findings suggest that weekly D/EPI is feasible and active in heavily pretreated advanced CRPC patients and seem to support the hypothesis that the addition of EPI to D may lead to overcome the resistance to D in a subgroup of patients.


Subject(s)
Antineoplastic Combined Chemotherapy Protocols/therapeutic use , Prostatic Neoplasms, Castration-Resistant/drug therapy , Abiraterone Acetate/administration & dosage , Aged , Aged, 80 and over , Antineoplastic Combined Chemotherapy Protocols/adverse effects , Bone Neoplasms/drug therapy , Bone Neoplasms/secondary , Docetaxel , Drug Administration Schedule , Drug Resistance, Neoplasm/drug effects , Epirubicin/administration & dosage , Humans , Male , Middle Aged , Prostatic Neoplasms, Castration-Resistant/mortality , Prostatic Neoplasms, Castration-Resistant/pathology , Survival Analysis , Taxoids/administration & dosage , Treatment Outcome
2.
Histol Histopathol ; 27(10): 1327-32, 2012 10.
Article in English | MEDLINE | ID: mdl-22936451

ABSTRACT

The term pseudolymphoma refers to a heterogeneous group of benign reactive T-cell or B-cell lymphoproliferative processes of diverse causes that simulate lymphoma clinically and histologically but usually undergo spontaneous remission. Its pathogenesis is still unclear. The prognosis is good although some evidence suggests that pseudolymphoma may progress to lymphoma. Pseudolymphoma of the urinary tract is extremely rare. We herein report a case of pseudolymphoma of the renal sinus in a 70-year-old man, associated with a high grade urothelial carcinoma of the bladder and to a prostatic adenocarcinoma (Gleason score 6). A brief review of the literature is included. The kidney showed a well-defined, whitish soft mass which involved the renal sinus. Microscopically, the lesion of the renal sinus consisted of a proliferation of small to medium size lymphocytes (CD20 positive and Bcl-2 negative) sometimes arranged in hyperplastic follicular structures. The diagnosis was confirmed by molecular studies which showed an oligopolyclonal IgH rearrangement. To the best of our knowledge, this is the second case of pseudolymphoma with a complete molecular characterization ever described in the renal sinus and the first one associated with multiple urogenital carcinomas.


Subject(s)
Kidney Diseases/complications , Neoplasms, Multiple Primary/complications , Pseudolymphoma/complications , Adenocarcinoma/complications , Aged , Gene Rearrangement, B-Lymphocyte, Heavy Chain , Humans , Kidney Diseases/genetics , Kidney Diseases/immunology , Kidney Diseases/pathology , Male , Neoplasms, Multiple Primary/pathology , Prostatic Neoplasms/complications , Pseudolymphoma/genetics , Pseudolymphoma/immunology , Pseudolymphoma/pathology , Urinary Bladder Neoplasms/complications
3.
Br J Cancer ; 104(4): 613-9, 2011 Feb 15.
Article in English | MEDLINE | ID: mdl-21285986

ABSTRACT

BACKGROUND: This randomised phase II study compared the activity and safety of the combination docetaxel (D)/epirubicin (EPI) with the conventional treatment D/prednisone (P) in advanced castrate-resistant prostate cancer (CRPC) patients. MATERIALS AND METHODS: Patients were randomly assigned to D 30 mg m(-2) as intravenous infusion (i.v.) and EPI 30 mg m(-2) i.v. every week (D/EPI arm), or D 70 mg m(-2) i.v. every 3 weeks and oral P 5 mg twice daily (D/P arm). Chemotherapy was administered until disease progression or unacceptable toxicity. RESULTS: A total of 72 patients were enrolled in the study and randomly assigned to treatment: 37 to D/EPI and 35 to D/P. The median progression-free survival (PFS) was 11.1 months (95% CI 9.2-12.6 months) in the D/EPI arm and 7.7 months (95% CI 5.7-9.4 months) in the D/P arm (P=0.0002). The median survival was 27.3 months (95% CI 22.1-30.8 months) in the D/EPI arm and 19.8 months (95% CI 14.4-24.8 months) in the D/P arm (P=0.003). Both regimens were generally well tolerated. CONCLUSION: The treatment of advanced CRPC with weekly D combined with weekly EPI was feasible and tolerable, and led to superior PFS than the treatment with 3-weekly D and oral P.


Subject(s)
Antineoplastic Combined Chemotherapy Protocols/therapeutic use , Carcinoma/drug therapy , Epirubicin/administration & dosage , Prednisone/administration & dosage , Prostatic Neoplasms/drug therapy , Aged , Aged, 80 and over , Antineoplastic Combined Chemotherapy Protocols/administration & dosage , Antineoplastic Combined Chemotherapy Protocols/adverse effects , Carcinoma/pathology , Carcinoma/surgery , Disease Progression , Docetaxel , Drug Administration Schedule , Epirubicin/adverse effects , Feasibility Studies , Humans , Infusions, Intravenous , Male , Middle Aged , Orchiectomy , Prednisone/adverse effects , Prostatic Neoplasms/pathology , Prostatic Neoplasms/surgery , Taxoids , Treatment Failure
5.
Chir Organi Mov ; 87(2): 103-7, 2002.
Article in English, Italian | MEDLINE | ID: mdl-12508709

ABSTRACT

Subtrochanteric fractures are a typical pathology in the elderly patient, they are not very common and they are difficult to treat. The general conditions of these patients, often at the limit of operability, are further compromised by surgery and time spent in bed, leading to the death of the patient in a high percentage of cases. The fracture is often spyroid, it has multiple fragments, with interruption of the medial cortical bone. The quality of the bone, because of the marked osteoporosis, does not guarantee the good hold of the means of fixation used. The use of intramedullary nailing is a safe method, that allows for stabilization of the fracture without excessive blood loss, it allows for early partial weight-bearing and it has a lower number of complications as compared to other methods. Between 1-1-97 and 31-12-00 a total of 59 persubtrochanteric fractures were treated; there were 15 males and 44 females. A Gamma Long nail was used in 46 cases, a Gamma Standard in 13. Eleven of the patients died within 6 months. A total of 27 patients aged an average of 78 years (minimum 65, maximum 87) were evaluated at a mean follow-up of 10 months (minimum 7, maximum 27). A Gamma Long nail had been used in 18 cases, and Gamma Standard in 8. Partial weight-bearing was allowed after a mean of 20 days (minimum 10, maximum 35), total weight-bearing after a mean of 60 days (minimum 40, maximum 75). Consolidation was obtained after a mean of 4 months (minimum 3, maximum 7). There were no significant complications.


Subject(s)
Fracture Fixation, Intramedullary , Hip Fractures/surgery , Age Factors , Aged , Aged, 80 and over , Female , Follow-Up Studies , Hip Fractures/diagnostic imaging , Humans , Male , Radiography , Time Factors
6.
Int J Cancer ; 91(1): 55-9, 2001 Jan 01.
Article in English | MEDLINE | ID: mdl-11149420

ABSTRACT

It has been proposed that oxidative stress develops in tumors, with important consequences for growth and progression. To investigate this hypothesis, we measured low m.w. thiols, disulfides, protein-mixed disulfides and a pool of major anti-oxidant enzymes in renal-cortex as well as renal-cell carcinoma (RCC) specimens at stages I-II and III. Our data showed (i) a significant increase in the levels of total intracellular glutathione at both tumor stages (levels were 2.6-2.8 fold higher than those in the normal renal cortex), (ii) a marked lowering of the GSH/GSSG ratio in stage I-II accompanied by a significant decrease of many GSH-dependent enzymes (i.e., GPX, GST, GGT, GR) and (iii) unchanged GSH/GSSG ratio and GSH-dependent enzyme activity in stage III with respect to normal renal cortex. These results indicate that relevant variations exist in the glutathione antioxidant system in the different stages of RCC and support the hypothesis that oxidative stress plays an important role in RCC growth and progression.


Subject(s)
Antioxidants/metabolism , Carcinoma, Renal Cell/metabolism , Glutathione/biosynthesis , Kidney Neoplasms/metabolism , Adult , Aged , Aged, 80 and over , Catalase/biosynthesis , Cell Division , Disease Progression , Disulfides/metabolism , Female , Glucosephosphate Dehydrogenase/biosynthesis , Glutamate-Cysteine Ligase/biosynthesis , Glutathione Reductase/biosynthesis , Glutathione Transferase/biosynthesis , Humans , Kidney Cortex/metabolism , Male , Middle Aged , Oxidation-Reduction , Oxidative Stress , Sulfhydryl Compounds/metabolism , Superoxide Dismutase/biosynthesis , gamma-Glutamyltransferase/biosynthesis
8.
Cancer ; 77(2): 344-51, 1996 Jan 15.
Article in English | MEDLINE | ID: mdl-8625244

ABSTRACT

BACKGROUND: The aim of this randomized Phase II study was to compare the efficacy and toxicity of a cisplatin-containing regimen with a carboplatin-containing regimen for patients with recurrent or metastatic bladder cancer. METHODS: Fifty-seven patients with recurrent or metastatic bladder cancer were randomized to receive M-VEC treatment (methotrexate, vinblastine, epirubicin, and cisplatin) (n = 29) or M-VECa treatment (methotrexate, vinblastine, epirubicin, and carboplatin) (n = 28). The chemotherapy was scheduled at 28-day intervals. Recombinant granulocyte-colony stimulating factors were administered daily when the absolute neutrophil count fell below 1000/mm3. The development of ototoxicity was evaluated by measuring auditory brain stem response. RESULTS: Of the 57 entered patients, 55 were evaluable for response and toxicity. The overall clinical response rate was 71% (with 25% complete responses) in the M-VEC group and 41% (with 11% complete responses) in the M-VECa group (P = 0.04). M-VEC chemotherapy was associated with more pronounced side effects. There was a statistically significant difference between M-VEC and M-VECa in terms of gastrointestinal toxicity (P = 0.04), nephrotoxicity (P = 0.03), and neurotoxicity (P = 0.02) during Cycle 3 of chemotherapy. Leukopenia and neutropenia were worse in the M-VECa arm, but not significantly so (P = 0.4). Ototoxicity was only detected in one of seven examined M-VEC patients after two cycles of chemotherapy. CONCLUSIONS: M-VECa has a low level of gastrointestinal, renal, neurologic, and otologic toxicity, but is apparently less effective than M-VEC in the treatment of recurrent or metastatic bladder cancer. However, a larger, randomized Phase III trial is needed to confirm these results.


Subject(s)
Antineoplastic Combined Chemotherapy Protocols/therapeutic use , Carboplatin/therapeutic use , Cisplatin/therapeutic use , Urinary Bladder Neoplasms/drug therapy , Aged , Antineoplastic Combined Chemotherapy Protocols/adverse effects , Epirubicin/therapeutic use , Female , Humans , Male , Methotrexate/therapeutic use , Middle Aged , Neoplasm Metastasis , Neoplasm Recurrence, Local , Vinblastine/therapeutic use
10.
Eur Radiol ; 6(3): 339-45, 1996.
Article in English | MEDLINE | ID: mdl-8798003

ABSTRACT

The purpose of this study was to investigate the accuracy of endorectal coil MRI in the local staging of prostate carcinoma. A total of 73 patients with biopsy-proven prostate carcinoma were examined at 0.5 T prior being submitted to radical prostatectomy. The gold standard was provided in all patients by findings at whole-mount sectioning of the surgical specimens. At pathology 28 patients had stage T2, 30 had stage T3a/b, and 15 had stage T3c lesions. Overall accuracy of endorectal coil MRI in defining local tumor stage was 82% (60 of 73 patients). Of 73 patients, 5 (7%) were underestimated and 8 (11%) overestimated. The sensitivity and the specificity of endorectal coil MRI in diagnosing capsular penetration were 95% and 82%, respectively. Seminal vesicle invasion was detected with 80% sensitivity and 93% specificity. Our data indicate that endorectal coil MRI is an accurate method for local staging of prostate cancer.


Subject(s)
Magnetic Resonance Imaging , Prostatectomy , Prostatic Neoplasms/pathology , Humans , Magnetic Resonance Imaging/instrumentation , Magnetic Resonance Imaging/methods , Male , Neoplasm Staging , Prostate/pathology , Prostatic Neoplasms/diagnosis , Sensitivity and Specificity
11.
Scand J Urol Nephrol ; 29(2): 219-22, 1995 Jun.
Article in English | MEDLINE | ID: mdl-7569802

ABSTRACT

Transitional cell carcinoma of the superior calyces was found 1 year after ipsilateral partial nephrectomy for renal adenocarcinoma. The main special features of the case are the rare occurrence of two primary tumours in the same kidney and the previous conservative surgery. A review of the literature has revealed no earlier case of this type.


Subject(s)
Carcinoma, Renal Cell/surgery , Carcinoma, Transitional Cell/surgery , Kidney Neoplasms/surgery , Neoplasms, Multiple Primary/surgery , Nephrectomy , Carcinoma, Renal Cell/pathology , Carcinoma, Transitional Cell/pathology , Humans , Kidney/pathology , Kidney Calices/pathology , Kidney Calices/surgery , Kidney Neoplasms/pathology , Male , Middle Aged , Neoplasms, Multiple Primary/pathology
12.
Scand J Urol Nephrol ; 29(1): 39-43, 1995 Mar.
Article in English | MEDLINE | ID: mdl-7618049

ABSTRACT

In the last years the role of capsaicin sensitive innervation, in the activation of the micturition reflex, has been reported in many papers. In our experience, upon the intravesical administration of capsaicin in humans, we noticed an increase of diuresis. No interaction is known about the sensory innervation of the bladder and renal function, so we studied the possibility of the existence of a vesical-renal reflex arc. Twenty-one patients (9 men and 12 women) were randomised to receive intravesical infusion of saline solution containing 10 microM capsaicin. Urine output, glomerular renal filtrate (GRF) and effective plasma renal flow (EPRF), measured by Technetium-99m diethylenetetramine-penta-acetic acid (DTPA) renal scintigraphy, were recorded over twenty minutes before and after the intravesical administration of capsaicin. Urine density, [Na+] and [K+] concentration, and prostaglandin E2 excretion were also determined before and after intravesical administration of capsaicin or vehicle. Installation of saline solution containing 10 microM capsaicin produced a significant increase of mean urine output, an increase of GRF, of EPRF and of [Na+] and [K+] urine concentration. An increase, not statistically significant, was observed of PgE2 excretion. None of the patients treated with vehicle showed any modification of parameters examined. The present findings demonstrate a hitherto unrecognized effect: increased diuresis following selective chemical stimulation of bladder efferents with capsaicin. The renal diuretic response to intravesical capsaicin represents a working hypothesis about the possible involvement of a vesical-renal reflex arc organized at spinal or supraspinal level.


Subject(s)
Capsaicin/pharmacology , Diuresis/drug effects , Kidney/physiology , Natriuresis/drug effects , Reflex/drug effects , Urinary Bladder/physiology , Administration, Intravesical , Aged , Female , Humans , Kidney/drug effects , Male , Middle Aged , Urinary Bladder/drug effects
13.
J Urol ; 153(2): 389-91, 1995 Feb.
Article in English | MEDLINE | ID: mdl-7815593

ABSTRACT

We report a case of autotransplantation performed 21 years ago in a patient suffering from intractable loin pain. Long-term followup, the pathogenesis of pain in regard to renal innervation and the value of autotransplantation as a form of complete sensory denervation are discussed.


Subject(s)
Kidney Transplantation , Pain, Intractable/surgery , Adult , Female , Follow-Up Studies , Humans , Time Factors
14.
J Urol ; 153(1): 135-6, 1995 Jan.
Article in English | MEDLINE | ID: mdl-7966747

ABSTRACT

We report our first experience with the use of a small gastric patch for reconstruction of the renal pelvis. We performed left gastropyeloplasty based on the right gastroepiploic artery in 1 patient suffering from recurrent urinary tract infections and renal stones, and moderate renal failure. The use of a gastric patch for reconstruction of the renal pelvis prevented the recurrence of calculi and bacterial infections, and produced an improvement in renal function. We confirm the feasibility of the use of a small gastric patch in reconstruction of the renal pelvis and we argue that there are several possible ways to use stomach in upper urinary tract reconstruction.


Subject(s)
Kidney Calculi/prevention & control , Kidney Pelvis/surgery , Renal Insufficiency/prevention & control , Stomach/surgery , Urinary Tract Infections/prevention & control , Female , Humans , Methods , Middle Aged , Recurrence
15.
Scand J Urol Nephrol ; 28(4): 409-12, 1994 Dec.
Article in English | MEDLINE | ID: mdl-7886417

ABSTRACT

Capsaicin-sensitive primary afferents widely innervate the genitourinary tract and play an important role in the integration of various mechanisms which activate reflexes leading to penile erection. We investigated the effect of intraurethral capsaicin infusion in psychogenically impotent men. The 20 patients were prospectively randomized to four groups, each of five men. Group A received intraurethral infusion of saline solution, group B intraurethral capsaicin (10(-5) M), group C intracavernosal papaverine hydrochloride (8 mg) plus intraurethral saline infusion, and group D intracavernosal papaverine hydrochloride (8 mg) plus intraurethral capsaicin (10(-5) M). The penile response was recorded real-time. Intraurethral capsaicin induced penile erection, as did the papaverine injection, while saline infusion was without effect. The erectile response to intraurethral infusion of capsaicin is suggested to involve activation of a urethra-corpora cavernosa reflex arc. Further studies are necessary to clarify if this arc is integrated at central nervous system level or is locally triggered, and if it may have pathophysiologic implications.


Subject(s)
Capsaicin/therapeutic use , Erectile Dysfunction/drug therapy , Infusion Pumps , Papaverine/therapeutic use , Psychophysiologic Disorders/drug therapy , Capsaicin/pharmacology , Catheterization , Drug Therapy, Combination , Erectile Dysfunction/physiopathology , Erectile Dysfunction/psychology , Humans , Injections , Male , Middle Aged , Papaverine/pharmacology , Penile Erection/drug effects , Prospective Studies , Psychophysiologic Disorders/physiopathology , Psychophysiologic Disorders/psychology , Urethra/drug effects , Urethra/innervation
16.
J Pharmacol Exp Ther ; 267(2): 590-5, 1993 Nov.
Article in English | MEDLINE | ID: mdl-8246132

ABSTRACT

The tachykinin (NK2) receptor-mediating contraction of the human isolated bladder to NKA was investigated by studying the affinities of eight structurally different receptor-selective antagonists (linear peptides, cyclic peptides and pseudopeptides, nonpeptide NK2 receptor antagonists). The affinities of the antagonists were compared to those measured for the same ligands at the NK2 receptors previously characterized in the rabbit pulmonary artery and hamster trachea. In the presence of a cocktail of peptidase inhibitors (bestatin captopril and thiorphan, 1 microM each) no significant correlation was found between pA2 values measured in the human bladder vs. those measured in the other two NK2 receptor-bearing preparation. In the presence of the aminopeptidase inhibitor amastatin, however, pA2 values of linear antagonists bearing an N-terminal Asp residue MEN 10,207 and MEN 10,376 were significantly enhanced and these pA2 values were used for analysis; a significant correlation was found between pA2 values measured in the human urinary bladder and rabbit pulmonary artery. The pseudopeptide analog of NKA (4-10), MDL 28,564 which also bears a N-terminal Asp residue behaved as an agonist and its action was enhanced by amastatin. We conclude that the NK2 receptor-mediating contraction of the human urinary bladder smooth muscle is similar to that previously characterized in the rabbit pulmonary artery (NK2A receptor category); in the human bladder smooth muscle an amastatin-sensitive peptidase (possibly aminopeptidase A) limits biological activity of linear peptide derivatives of NKA bearing a N-terminal Asp residue.


Subject(s)
Peptides , Protease Inhibitors/pharmacology , Receptors, Neurokinin-2/antagonists & inhibitors , Urinary Bladder/ultrastructure , Adult , Aged , Aged, 80 and over , Amino Acid Sequence , Anti-Bacterial Agents/pharmacology , Drug Interactions , Humans , In Vitro Techniques , Middle Aged , Molecular Sequence Data , Muscle Contraction/drug effects , Muscle Contraction/physiology , Muscle, Smooth/drug effects , Muscle, Smooth/physiology , Neurokinin A/analogs & derivatives , Neurokinin A/pharmacology , Peptide Fragments/pharmacology , Tachykinins/pharmacology , Urinary Bladder/drug effects , Urinary Bladder/enzymology
17.
Regul Pept ; 47(2): 151-8, 1993 Sep 03.
Article in English | MEDLINE | ID: mdl-8234901

ABSTRACT

The activity and selectivity of MEN 10,573 and MEN 10,612, novel cyclic pseudopeptides which are selective tachykinin NK-2 receptor antagonists is described, as compared to that of previously characterized linear and cyclic compounds. For the NK-2 receptor, the activity of test compounds was investigated in the hamster isolated trachea (HT) and the endothelium-deprived rabbit isolated pulmonary artery (RPA), two preparations which are endowed with pharmacologically distinct forms of the NK-2 receptor. The novel cyclic pseudopeptides, MEN 10,573 and MEN 10,612 displayed very high affinity for the NK-2 receptor in the HT (pA2 8.66 and 9.06, respectively) which is higher than that observed in the RPA (pA2 7.31 and 7.41 for MEN 10,573 and MEN 10,612, respectively). The antagonism exerted by MEN 10,573 and MEN 10,612 was of competitive nature in both preparations. MEN 10,573 and MEN 10,612 also displayed competitive antagonism for NK-2 receptor-mediated responses in the rabbit bronchus (RB), rat vas deferens (RVD), circular muscle of the human colon (HUC) and ileum (HUI). In the RB, HUC and HUI, the potency of the novel cyclic pseudopeptides was comparable to that of MDL 29,913 and about 10-fold greater than that of L659,877. In the RVD however, the potency of MEN 10,573 MEN 10,612 or MDL 29,913 was similar to that of L659,877. In anaesthetized rats, i.v. injection of MEN 10,612 produced a selective and long-lasting blockade of the urinary bladder contraction produced by the i.v. injection of the NK-2 receptor selective agonist [beta Ala8]neurokinin A(4-10), without affecting the response to the NK-1 receptor selective agonist [Sar9]substance P sulfone.(ABSTRACT TRUNCATED AT 250 WORDS)


Subject(s)
Peptides, Cyclic/pharmacology , Receptors, Neurokinin-2/antagonists & inhibitors , Amino Acid Sequence , Animals , Binding, Competitive , Cricetinae , Guinea Pigs , Humans , In Vitro Techniques , Kinetics , Male , Molecular Sequence Data , Rabbits , Rats , Rats, Wistar
18.
Br J Urol ; 71(6): 686-91, 1993 Jun.
Article in English | MEDLINE | ID: mdl-8343895

ABSTRACT

We have extended our earlier observations on pain relief produced by intravesical instillation of capsaicin (10 microM in saline) in patients with hypersensitive disorders of the lower urinary tract. Patients in group A (n = 15) received intravesical capsaicin on days 0, 14 and 28: on each occasion the drug produced a warm or burning sensation, reduction in bladder capacity and a delayed, transient improvement or disappearance of symptoms. Patients in group B (n = 5) received intravesical capsaicin (10 microM at cystometry) 3 times on day 0. The initial sensation of warmth was experienced on each occasion, indicating that no significant desensitisation has been produced by the first instillation. Clinical improvement similar to that found in group A was observed. Three patients (group C) received warm saline (42 degrees C) at cystometry. This produced a pricking sensation, no change at cystometry and no subjective clinical improvement. Apart from the initial sensation of warmth, no patient in group A or B experienced side effects, either local or systemic. These findings confirm that intravesical instillation of capsaicin has a beneficial effect on patients with hypersensitive bladder disorders. Counter-irritation rather than desensitisation of primary afferents could be a possible mechanism of action. Further studies are needed to establish whether the intravesical administration of capsaicin or capsaicin-like agents represents a new form of treatment for relief of bladder pain.


Subject(s)
Capsaicin/administration & dosage , Sensation Disorders/drug therapy , Urinary Bladder Diseases/drug therapy , Administration, Intravesical , Adult , Aged , Capsaicin/adverse effects , Drug Administration Schedule , Female , Humans , Male , Middle Aged , Pain/chemically induced , Pain/drug therapy , Sensation Disorders/chemically induced , Sensation Disorders/physiopathology , Urinary Bladder Diseases/chemically induced , Urinary Bladder Diseases/physiopathology , Urination/drug effects
19.
Gastroenterology ; 102(1): 88-96, 1992 Jan.
Article in English | MEDLINE | ID: mdl-1370160

ABSTRACT

The effects of some newly developed tachykinin antagonists that are selective for the neurokinin (NK)-1 (L 668,169) or the NK-2 (MEN 10,207, L 659,877 and R 396) tachykinin receptor on the cholinergic and noncholinergic contraction and on the nonadrenergic noncholinergic relaxation produced by electrical field stimulation (50 Hz) were investigated in mucosa-free circular strips of the human ileum. The strips were contracted by substance P and neurokinin A as well as by selective NK-2-receptor ligands, [beta Ala8]neurokinin A(4-10), and MDL 28,564, the latter peptide being capable of discriminating between NK-2-receptor subtypes. The selectivity of the antagonists for NK-1 or NK-2 receptors was confirmed in pharmacological experiments using substance P, neurokinin A, and [beta Ala8]neurokinin A(4-10) as stimulants. Among the NK-2-selective antagonists, MEN 10,207 displayed the highest affinity, followed by L 659,877 and R 396. The antagonists MEN 10,207 and L 659,877 inhibited the noncholinergic contraction to electrical stimulation in a concentration-dependent manner; L 668,169 and R 396 were poorly effective. Thus the potency of antagonists toward the noncholinergic response closely paralleled their rank order of potency at NK-2 receptors. The cholinergic contraction and nonadrenergic noncholinergic relaxation were not inhibited by the antagonists. Both substance P- and neurokinin A-like immunoreactivities were detected in extracts of the human ileum, and the identity of the corresponding peptides was confirmed by reverse-phase high-performance liquid chromatography. It was concluded that in addition to NK-1 receptors, the circular muscle of the human ileum also contains NK-2 receptors. Activation of the latter is chiefly responsible for the noncholinergic contraction to nerve stimulation.


Subject(s)
Ileum/drug effects , Muscle Contraction/drug effects , Nervous System Physiological Phenomena , Receptors, Neurotransmitter/physiology , Tachykinins/antagonists & inhibitors , Aged , Aged, 80 and over , Atropine/pharmacology , Electric Stimulation , Humans , Ileum/innervation , Ileum/metabolism , In Vitro Techniques , Middle Aged , Neurokinin A/metabolism , Radioimmunoassay , Receptors, Neurokinin-2 , Substance P/analysis , Tachykinins/pharmacology , Tetrodotoxin/pharmacology
20.
Eur J Pharmacol ; 203(3): 365-70, 1991 Oct 22.
Article in English | MEDLINE | ID: mdl-1723045

ABSTRACT

The contractile effect of substance P, neurokinin A, receptor selective agonists for tachykinin receptors and NK2 tachykinin receptor antagonists was investigated in mucosa-free circular strips of the human isolated colon. Neurokinin A and substance P produced concentration-dependent contractions which approached 80-90% of the maximal response to carbachol. Neurokinin A was about 370 times more potent than substance P. The action of neurokinin A and substance P was not modified by peptidase inhibitors (bestatin, captopril and thiorphan, 1 microM each). The NK2 receptor selective agonist, [beta-Ala8]neurokinin A-(4-10) closely mimicked the response to neurokinin A while NK1 and NK3 receptor selective agonists were active only at microM concentrations. The pseudopeptide, MDL 28,564, which is one of the most selective NK2 ligands available, behaved as a full agonist. Responses to [beta-Ala8]neurokinin A were antagonized by NK2 receptor selective antagonists, with the rank order of potency MEN 10,376 greater than L 659,877 much greater than R 396. These data indicate that NK2 tachykinin receptors play a dominant role in determining the contraction of the circular muscle of the human colon to peptides of this family. The NK2 receptor subtype responsible for this effect belongs to the same subtype (NK2A) previously identified in the rabbit pulmonary artery and guinea-pig bronchi.


Subject(s)
Muscle, Smooth/metabolism , Receptors, Neurotransmitter/metabolism , Aged , Amino Acid Sequence , Colon/drug effects , Colon/metabolism , Humans , In Vitro Techniques , Ligands , Middle Aged , Molecular Sequence Data , Muscle Contraction/drug effects , Muscle, Smooth/drug effects , Neurokinin A/pharmacology , Peptides/pharmacology , Protease Inhibitors/pharmacology , Receptors, Neurotransmitter/antagonists & inhibitors , Receptors, Neurotransmitter/drug effects , Receptors, Tachykinin , Substance P/pharmacology , Tachykinins/pharmacology
SELECTION OF CITATIONS
SEARCH DETAIL
...